|
Onyx Pharmaceuticals' cancer drug could turn out to be a real gem. Working with health care behemoth Bayer, the biotechnology company developed Nexavar, an FDA-approved treatment for advanced kidney cancer and liver cancer. The partners are jointly promoting the drug in the US, while Bayer handles marketing duties in the European Union (where Nexavar was initially approved in 2006) and elsewhere. Onyx and Bayer are also testing the drug as a possible treatment for other kinds of cancer, both alone and in combination with other cancer therapies. Nexavar received approval as a liver cancer treatment in 2007. The company is seeking to widen into additional areas of drug development.
|
| | | Contact Information | |
Address: |
2100 Powell St.
Emeryville, CA 94608
| | Phone: | 510-597-6500 | | Fax: | 510-597-6600 |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2008): | 194.30 M | | Employees (2008): | 197 | | Employee Growth (1 yr): | 28.80% |
|
|
Key People
| | • |
President, CEO, and Director:
N. Anthony (Tony) Coles
| | • |
EVP and COO:
Laura A. Brege
| | • |
EVP and CFO:
Matthew K. (Matt) Fust
|
|
|
